Cepheid received Emergency Use Authorization from the U.S. FDA for its next-generation test to support the global fight against COVID-19 during the upcoming respiratory virus season. The test can provide rapid detection of the current coronavirus SARS-CoV-2 in as soon as 25 minutes for positive results* and provide results for all four pathogens in just 36 minutes with less than a minute of hands-on time.

About Cepheid
Based in Sunnyvale, Calif., Cepheid a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.

For Cepheid Media Inquiries:
Darwa Peterson


SOURCE Cepheid